[go: up one dir, main page]

AR026704A1 - CRYSTAL FORM - Google Patents

CRYSTAL FORM

Info

Publication number
AR026704A1
AR026704A1 ARP000106383A ARP000106383A AR026704A1 AR 026704 A1 AR026704 A1 AR 026704A1 AR P000106383 A ARP000106383 A AR P000106383A AR P000106383 A ARP000106383 A AR P000106383A AR 026704 A1 AR026704 A1 AR 026704A1
Authority
AR
Argentina
Prior art keywords
compound
refers
pharmaceutically acceptable
crystalline form
solvate
Prior art date
Application number
ARP000106383A
Other languages
Spanish (es)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9904417A external-priority patent/SE9904417D0/en
Priority claimed from SE0001422A external-priority patent/SE0001422D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR026704A1 publication Critical patent/AR026704A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a las formas cristalinas del compuesto ácido 3-{4-[2-(4-terc-butoxicarbonilaminofenil)etoxi}fenil}-(S)-2-etoxi propanoico, segunformula (1) o su sal farmacéuticamente aceptable, y cualquiera de sus solvatos. La presente también se refiere a los métodos para tratar una o más enfermedadesmetabolicas, particularmente aquellas asociadas con el Síndrome de Resistencia a la Insulina, y el uso de la forma cristalina del compuesto, o su salfarmacéuticamente aceptable, o su solvato , para la fabricacion de un medicamento para uso terapéutico en una o más enfermedades metabolicas. La presente ademásse refiere a las composiciones farmacéuticas que contienen a la forma cristalina del compuesto, o su sal farmacéuticamente aceptable , o su solvato, comoingrediente activo, así como también a los procesos para la fabricacion de la forma cristalina del compuesto, o su sal farmacéuticamente aceptable, o susolvato.This refers to the crystalline forms of the compound 3- {4- [2- (4-tert-butoxycarbonylaminophenyl) ethoxy} phenyl} - (S) -2-ethoxy propanoic acid, according to formula (1) or its pharmaceutically acceptable salt, and any of his solvates. This also refers to methods for treating one or more metabolic diseases, particularly those associated with Insulin Resistance Syndrome, and the use of the crystalline form of the compound, or its pharmaceutically acceptable, or solvate, for the manufacture of a medication for therapeutic use in one or more metabolic diseases. The present invention also refers to pharmaceutical compositions containing the crystalline form of the compound, or its pharmaceutically acceptable salt, or its solvate, as an active ingredient, as well as the processes for the manufacture of the crystalline form of the compound, or its pharmaceutically salt. acceptable, or susolvato.

ARP000106383A 1999-12-03 2000-12-01 CRYSTAL FORM AR026704A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9904417A SE9904417D0 (en) 1999-12-03 1999-12-03 Crystalline form
SE0001422A SE0001422D0 (en) 2000-04-17 2000-04-17 Crystalline form

Publications (1)

Publication Number Publication Date
AR026704A1 true AR026704A1 (en) 2003-02-26

Family

ID=26655079

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000106383A AR026704A1 (en) 1999-12-03 2000-12-01 CRYSTAL FORM

Country Status (3)

Country Link
AR (1) AR026704A1 (en)
AU (1) AU2034601A (en)
WO (1) WO2001040165A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
AU749505B2 (en) 1997-10-27 2002-06-27 Dr. Reddy's Laboratories Limited Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999016758A1 (en) 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
AU752059B2 (en) 1997-10-27 2002-09-05 Dr. Reddy's Laboratories Limited Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6531596B1 (en) 1998-10-29 2003-03-11 Dr. Reddy's Laboratories Ltd. Process for the preparation of new antidiabetic agents
JP2002528535A (en) 1998-10-29 2002-09-03 ドクター・レディーズ・リサーチ・ファウンデーション An improved method for producing new antidiabetic agents
US6897199B2 (en) 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA26634A1 (en) * 1998-06-04 2004-12-20 Astra Ab NOVEL 3-ARYL PROPIONIC ACID DERIVATIVES AND THE LIKE
SE9801990D0 (en) * 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs

Also Published As

Publication number Publication date
AU2034601A (en) 2001-06-12
WO2001040165A1 (en) 2001-06-07

Similar Documents

Publication Publication Date Title
AR029412A1 (en) CRYSTAL FORM
CL2004000382A1 (en) TETRAHYDROISOQUINOLINAS REPLACED, PREPARATION PROCESS, AND PHARMACEUTICAL COMPOSITION, USEFUL IN THE TREATMENT AND PREVENTION OF PATHOLOGICAL STATES THAT ARE RELIEFED WITH A 5-HT6 AGONIST.
ECSP055774A (en) NEW MEDICATION FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
AR077478A2 (en) DERIVATIVES OF OXINDOL REPLACED DRUGS THAT UNDERSTAND AND USE THEMSELVES
UY28510A1 (en) CHEMICAL COMPOUNDS
ECSP066950A (en) ADRENOCEPTOR-BETA2 GLICOPIRROLATE AND AGONIST COMBINATIONS
CO5271715A1 (en) 7-AZA-INDOLIN-2-WAVES SUBSTITUTED IN 4 AND ITS USE AS PROTEIUNA QUINASA INHIBITORS
ATE495155T1 (en) HETEROCYCLIC INHIBITORS OF MEK
AR057712A1 (en) DIHYDROPTERIDINONES IN THE TREATMENT OF RESPIRATORY DISEASES
AR029766A1 (en) QUINASE INHIBITOR COMPOUND AND USE OF IT TO PREPARE A PHARMACEUTICAL COMPOSITION
UY30316A1 (en) SUBSTITUTED DERIVATIVES OF BENZAMIDS, NICOTINAMIDS, PROPANAMIDS, ACETAMIDS AND CARBOXAMIDS N- (2- (PIPERIDIN-1-ILMETIL) CICLOHEXIL) REPLACED, PREPARATION PROCESSES, COMPOSITIONS CONTAINING AND APPLICATIONS
AR029211A1 (en) DERIVATIVES OF OXAZOLES, THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND THEM
AR029456A1 (en) SHREDDED FORM
NO20065904L (en) Therapeutic compounds
AR054347A1 (en) THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION
AR056575A1 (en) COMPOSITE OF (ALPHA) -AMINOCARBOXYAMIDE THAT IS 5- (4 - [[(2-FLUOROPHENYL) METHYL] OXI] PHENYL) PROLINAMIDE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AND PROCESS TO PREPARE IT
ATE331711T1 (en) ANTI-INFLAMMATORY 3-ARYLTHIO-3-THIAZOLYLALKYLAMINE
UY27018A1 (en) PIRIMIDINE DERIVATIVES
AR026704A1 (en) CRYSTAL FORM
UY27959A1 (en) NEW AGARIST PPAR ALFA AND PPAR RANGE
ES2129448T3 (en) USE OF 2- (2-NITRO-4-TRIFLUOROMETILBENZOIL) -1,3-CYCLLOHEXANODIONA IN THE TREATMENT OF THYROSINEMIA AND PHARMACEUTICAL COMPOSITIONS.
AR001769A1 (en) Benzamide enterokinetics pharmaceutical compositions containing them, a process for the preparation of said pharmaceutical compositions, the use of said compounds for the manufacture of medicines and a process for their preparation.
AR042547A1 (en) USE OF ALPHA - PHENYLTIOCABOXYL AND ALPHA - PHENYLOXYCARBOXYL ACIDS WITH DECREASING ACTIVITY OF GLUCOSE IN THE SERUM AND LIPIDS IN THE SERUM
AR026705A1 (en) SHREDDED FORM
UY27074A1 (en) AMINOTRIAZOLOPIRIDINE DERIVATIVES

Legal Events

Date Code Title Description
FB Suspension of granting procedure